Websitewww.shionogi.co.jp Telephone81 6 62022161 No of Employees5,693 IndustryPharmaceuticals and Healthcare Ticker Symbol & Exchange4507 (TYO) Revenue (2024)$3.0B12.8%(2024 vs 2023) EPSXYZ Net Income (2024)XYZ2.1%(2024 vs 2023) Market Cap*$15.8B ...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that ...
E-Healthcare Naluri Hidup Sdn. Bhd. Creandum Advisor AB Digital Health Market Digital Therapeutics Market Therapeutic Area Merck & Co., Inc. Chugai Pharmaceutical Co., Ltd. Anti-obesity Therapeutics Market Cystic Fibrosis Disease Insights and Market [+n] Innovation Matrix Analysis include all subsi...
“这些结果表明,与安慰剂相比,S-217622 可迅速消除患者体内的 SARS-CoV-2,这标志着它在获得批准后作为 COVID-19 的有效治疗选择的潜力。随着全球范围内感染的持续增加,重要的是我们能够获得一系列易于管理的治疗方案,以减轻我们医疗保健系统的压力,”Shionogi & Co 总裁兼首席执行官 Isao Teshirogi 博士说。 , ...
盐野木(香港)有限公司与Tutum Japan Healthcare Limited的合资企业,是中国平安保险海外(控股)有限公司的子公司,也是中国平安保险(集团)股份有限公司的间接子公司., 2020年成立于 主要业务包括对包括中国在内的亚洲国家的资本投资、知识产权许可管理和产品进出口业务。
Shionogi & Co., Ltd. OTCPK:SGIO.F -1.4% GSK plc OTCPK:GLAX.F -0.7% 礼来公司 NYSE:LLY 3.9% Healthcare SECTOR:HLTH.JP 5.1% Nippon Shinyaku Co Ltd TSE:4516 5.4% 武田药品 TSE:4502 8.8% ASKA Pharmaceutical Holdings Co Ltd TSE:4886 9.0% 卫材 TSE:4523 10.2% Supernus Pharmaceuticals Inc ...
我们发现下列公司与Shionogi & Co Ltd ADR相近,它们都属于相关的行业。我们还考虑了规模、增长和各种财务指标,并将列表缩小到以下范围。 Shionogi ADR的今日盘后价格百分比变动基准 名称代码今日盘后价格百分比变动 礼来公司NYSE:LLY-0.2% HealthcareSECTOR:HLTH.JP0.0% ...
(Ping An-Shionogi), a joint venture between Ping An and Shionogi & Co., Ltd., has been launched in Shanghai. Ping An-Shionogi is a Healthcare as a Service (HaaS) enterprise, an integrated medical and healthcare platform, for public health and patients....
Shionogi & Co Ltd ADR的格雷厄姆估值计算公式于March 2022触及5年低点,是4.84。 Shionogi & Co Ltd ADR的格雷厄姆估值计算公式于2021 (6.55, -9.1%)、2022 (4.84, -26.0%)和2024 (6.63, -30.3%)减少和于2020 (7.20, +9.1%)和2023 (9.50, +96.3%)增加。
Global Investments Pte. Ltd, along with existing investors like Sofilaro, ARIS, SudPME, and UVM Health Capital. This funding will enable Cilcare to initiate two Phase 2a clinical trials in 2025 across Europe and the United States for its lead candidate, CIL001, a treatment targeting cochlear ...